Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, has successfully completed its merger with Biosight, Ltd. The merged entity will operate under the name Ayala Pharmaceuticals, Inc. and continue trading on the OTCQX with the ticker symbol “ADXS.” This merger expands Ayala’s product pipeline, adding aspacytarabine (BST-236), a novel antimetabolite in clinical development for AML. The company remains committed to its Phase 3 RINGSIDE study for AL102 in desmoid tumors and its mission of advancing innovative therapies for rare tumors and aggressive cancers. The leadership team and board composition have also been announced.
Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced the closing of its merger with Biosight, Ltd. (“Biosight”), pursuant to which Ayala acquired Biosight. The combined company will operate under the name Ayala Pharmaceuticals, Inc., and its shares will continue to trade on the OTCQX under Ayala’s current ticker symbol (“ADXS”).
“We are pleased to close the merger with Biosight which expands our product pipeline,” said Ken Berlin, President & CEO. “We have added aspacytarabine (BST-236), a novel antimetabolite, which is in clinical development for AML and could potentially serve as a superior backbone therapy for unfit AML as part of combination treatment regimens. Our primary focus continues to be completing the ongoing Phase 3 RINGSIDE study evaluating AL102 in desmoid tumors and we look forward to continuing our mission of bringing innovative therapies to people with rare tumors and aggressive cancers.”
Management and Organization
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
As previously announced, the combined company will be led by Ayala’s existing senior management team, with Ken Berlin serving as President and CEO; Andres Gutierrez, MD, PhD, Executive VP and Chief Medical Officer; and Dana Gelbaum, MSc, MBA, General Manager and Chief Business Officer. Roy Golan, CPA, LLM, previously Executive VP & CFO of Biosight, has been appointed Chief Financial Officer of the combined company. The board of directors of the combined company is comprised of David Sidransky, MD (Chairman); Robert Spiegel, MD, FACP; Murray Goldberg; Vered Bisker-Leib, PhD, MBA; Roni Appel, MBA; Pini Orbach, PhD; Yuval Cabilly, PhD; and Ken Berlin, with an additional board member expected to be added at a later date.
Source: Biospace
